MedTrace Logo

Stem Cell Therapy for Chronic Kidney Disease

NCT04869761 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-06-06

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.

Conditions

  • Chronic Kidney Diseases
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus
  • Diabetic Nephropathies

Interventions

DRUG

Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion

Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery

DRUG

Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions

Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery

Sponsors & Collaborators

  • LaTonya J. Hickson

    lead OTHER

Principal Investigators

  • LaTonya Hickson, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2023-04-26
Completion
2023-04-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04869761 on ClinicalTrials.gov